Medical News Daily - Issue 3891 (July 14): IVD Giant Forecasts 62% H1 Net Profit Surge; Huawei Launches Global Education & Healthcare Partners Alliance

1. Qinghai Launches "Medical Insurance Image Cloud" for Nationwide Interconnectivity in China

Recently, Qinghai Successfully Completes the Deployment of Medical Insurance Imaging Cloud

2. Johnson & Johnson Launches VARIPULSE Ablation Platform in Asia-Pacific

Recently, Johnson & Johnson Medical Technologies officially launched the VARIPULSE ablation platform in the Asia-Pacific region, a revolutionary technology for treating atrial fibrillation (AF). This platform will transform the treatment landscape for AF patients in the region. The core breakthrough of the VARIPULSE platform lies in the first-ever integration of ablation and mapping into the CARTO 3 single workflow. This innovation addresses the biggest clinical pain point of PFA technology. The three-dimensional cardiac electroanatomical mapping technology enables real-time visualization, significantly improving the precision and efficiency of AF treatment. The procedure generally eliminates the need for X-ray fluoroscopy and is compatible with both deep sedation and conscious sedation protocols, markedly reducing the risk of damage to adjacent tissues such as the esophagus, pulmonary veins, and phrenic nerve. (Innovation Network of Medical Devices)

3. The "Digital Therapy Center for Respiratory Chronic Diseases" at the grassroots level has been established in Wenchang.

Recently, the "Respiratory Chronic Disease Digital Therapy Center" at the Dongjiao Town Central Health Center in Wenchang City, Hainan Province, was officially inaugurated. In 2024, chronic obstructive pulmonary disease (COPD) was included in China’s national basic public health service programs, presenting new requirements for precision and continuity of care at the grassroots level. Traditional models have significant shortcomings in patient screening, medication guidance, and ensuring treatment adherence. In recent years, Hainan Province has introduced a series of support policies to accelerate the development of the digital health industry. The Dongjiao Town Central Health Center has taken the lead in adopting advanced concepts, focusing on high-burden respiratory diseases like COPD, and establishing the "Respiratory Chronic Disease Digital Therapy Center." Through the integration of "one network, one platform," it addresses key pain points in grassroots diagnosis and treatment. It is reported that the "Respiratory Chronic Disease Digital Therapy Center" at the Dongjiao Town Central Health Center in Wenchang City is the second grassroots model of its kind in China. Since its trial operation, it has achieved a nearly threefold increase in the positive detection rate of COPD and a lung function test quality control compliance rate of over 99%. (CNR News)

4. Huawei Launches Global Education and Healthcare Partner Alliance

Recently, during the China Week of the 2025 Global Education and Healthcare Partners hosted by Huawei, the company successfully held the Education and Healthcare Industry Partner Summit. At the summit, Huawei launched the Global Education and Healthcare Partner Alliance (GEHPA) program, aiming to enhance communication among industry partners, complement each other's strengths, and achieve win-win cooperation. Representatives from partners such as Chinasoft International, Wenhua Online, Chengdu Sobey, Wisdom Education Future, Neusoft Medical, Hui Every Technology, Maitai Technology, MAHARAT 71 from the UAE, PTC from Singapore, ITSOFT from Spain, and BSC from Rwanda attended and witnessed the launch of the Global Education and Healthcare Partner Alliance. According to Huawei’s announcement, the alliance will be managed daily by the Partner Development Department of Huawei's Public Affairs Group, providing a brand-new communication platform for education and healthcare industry partners worldwide. Alliance members can carry out collaborative cooperation in areas such as joint innovation, cutting-edge technology research, joint solution development, and sharing business opportunities. (IT Home)

5. Orthopedic Giant Launches Portable Bone Healing Device

Recently, Enovis Corporation announced the launch of the Manafuse® Bone Growth Stimulator, a portable, battery-powered medical device that utilizes low-intensity pulsed ultrasound (LIPUS) technology for the non-invasive treatment of fresh fractures and non-unions. The Manafuse® Bone Growth Stimulator accelerates fracture healing by emitting LIPUS signals to activate the body’s natural healing processes. It comes equipped with a non-sterile transducer, fixation strap, and gel. Proper placement must be confirmed by a healthcare professional using radiographic imaging or anatomical landmarks, with the application site marked on the patient’s skin using an indelible marker. Key features include: Portability and ease of use: Manafuse is a portable, battery-operated device designed for home use, wearable over casts, braces, or clothing. LIPUS technology: By emitting low-intensity pulsed ultrasound signals, it stimulates bone cell (osteoblast) division and growth, activating the body's natural healing process. (SiYu MedTech)

6. Exactech Scapula Reconstruction System Receives FDA Approval

Recently, Exactech announced that the Equinoxe® Scapula Reconstruction System has received 510(k) clearance for use in acromion and scapular spine fractures. Acromion and scapular fractures are rare but serious complications that can occur with any reverse total shoulder arthroplasty (rTSA) implant design. Reports indicate that the average incidence of acromion and scapular fractures following rTSA is 2.8%, but for certain patient diagnoses, this rate may reach up to 10.9%. The Equinoxe Scapula Reconstruction System allows orthopedic surgeons to employ various techniques to treat scapular fractures, including single-plate and dual-plate fixation, regardless of the placement of any specific reverse total shoulder arthroplasty (rTSA) implant design. This innovative system offers a range of versatile anatomically contoured plates with multiple length options, designed to enable precise fracture management tailored to different patient anatomies to restore function. (CISION)

7. What is the medical device public service platform?

The Medical Device Public Service Platform is a key initiative co-developed by the Oshine Group in collaboration with local governments, industrial parks, medical institutions, and research universities. It focuses on incubating, transforming, and investing in cutting-edge and innovative global medical device projects. By establishing scientific research and technology transfer mechanisms that align with international standards, the platform operates under an open and shared model. This attracts top-tier researchers, doctors, and innovators from around the world to join, providing comprehensive industry technical services that integrate R&D transformation, incubation, and investment. The platform aims to nurture innovative medical device achievements with significant innovation and application value, offering strong support for promoting the development of the medical device industry and technological innovation. (Compiled by Oshine)

8. IVD Giant's Net Profit Estimated to Surge 62% in First Half of the Year

Recently, Suzhou Nano-Micro Technology Co., Ltd. released its 2025 half-year earnings forecast, predicting operating revenue of 400 million to 420 million yuan, representing a year-on-year increase of 18% to 24%; net profit attributable to shareholders of 61 million to 73 million yuan, up 35% to 62% year-on-year; and non-recurring net profit of 55 million to 65 million yuan, reflecting a year-on-year growth of 51% to 78%. The growth in Nano-Micro Technology's performance is mainly attributed to its focus on the core businesses of separation and purification as well as analytical testing, particularly with revenue from chromatography media and column products achieving approximately 20% growth. This voluntarily disclosed forecast enhances market expectations for Nano-Micro Technology’s first-half business performance, with the final results to be confirmed in the official half-year report. (IVD Network)